Co-agonists at the receptors for glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP) are among the best-in-class drugs to treat obesity and type 2 diabetes [1]. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.